Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corporation director Marc Stapley reported exercising stock options for 15,000 shares of common stock at an exercise price of
Glaukos Corporation’s President and COO, Joseph E. Gilliam, reported option exercises and related share sales. On January 22, 2026, he exercised stock options for 10,498 shares of common stock at an exercise price of $55.18 per share, from options originally granted on March 24, 2022 that were tied to multi-year performance goals and operational targets.
On the same date, he sold blocks of Glaukos common stock totaling 2,406, 3,100, 1,798 and 3,194 shares at weighted average prices of $126.10, $127.03, $128.07 and $129.28, respectively. These transactions, as well as the option exercises, were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, Gilliam beneficially owned 92,366 shares of common stock, which includes 62,605 restricted stock units that have not yet vested or been delivered.
Glaukos Corporation’s president and COO, Joseph E. Gilliam, reported option exercises and a share sale. On January 21, 2026, he exercised stock options for 2,602 and 1,900 shares of common stock at an exercise price of $55.18 per share. This resulted in the acquisition of 4,502 common shares, which were then sold the same day at a weighted average price of $124.65 per share, in trades ranging from $124.47 to $124.75, under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, he directly holds 92,366 shares of common stock, including 62,605 restricted stock units that have not yet vested or been delivered.
Joseph Gilliam filed a notice of proposed sale of Glaukos common stock under Rule 144. The notice covers 10,498 common shares to be sold through Fidelity Brokerage Services LLC on or about 01/22/2026 on the NYSE, with an aggregate market value of
The 10,498 shares were acquired on 01/22/2026 via exercise of an option originally granted on 03/24/2022, paid for in cash. Over the prior three months, Joseph Gilliam sold 19,340 shares of common stock on 11/18/2025 for gross proceeds of
An affiliate of GKOS filed notice of intent to sell 15,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 01/22/2026. The filing lists an aggregate market value of these shares of
The 15,000 shares are tied to stock options originally granted on 06/02/2016 and acquired and paid for in cash on 01/22/2026. The person on whose behalf the sale is planned represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Glaukos insider Joseph Gilliam has filed a Form 144 notice to sell up to 4,502 shares of Glaukos common stock. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 01/21/2026 and an aggregate market value of 561167.76 based on the figures given. The filing notes that 57434740 shares of Glaukos common stock were outstanding.
The 4,502 shares were acquired on 01/21/2026 through the cash exercise of stock options that were originally granted on 03/24/2022 by the issuer. The notice also reports that during the past three months, Joseph Gilliam sold 19,340 shares of Glaukos common stock on 11/18/2025 for gross proceeds of 1740600.00.
Glaukos Corporation’s Chairman and CEO Thomas William Burns reported planned option exercises and share sales under a Rule 10b5-1 trading plan. On January 8 and 16, 2026, he exercised stock options with a strike price of $16.49 to acquire 88,055 and 186,945 shares of common stock, respectively, then sold the same numbers of shares at a price of $115 per share. Following these transactions, he reported 153,775 shares of common stock beneficially owned directly, which the filing notes includes 89,621 restricted stock units that have not yet vested or been delivered. He also reported additional indirect holdings in several Burns family-related trusts.
Glaukos Corporation insider Thomas Burns has filed a notice of proposed stock sales under Rule 144. The filing covers 186,945 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $21,498,675.00 and 57,434,740 shares of common stock outstanding.
The shares to be sold were acquired on January 16, 2026 through the cash exercise of a stock option that was originally granted on March 10, 2016, with 186,945 shares acquired and paid in cash on that date. Over the prior three months, Burns sold 88,055 shares of Glaukos common stock on January 8, 2026 for gross proceeds of $10,126,325.00.
Glaukos Corporation filed a current report describing new financial communications to the market. The company issued a press release with its preliminary, unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025, and furnished this release as Exhibit 99.1. Glaukos also prepared an investor presentation, furnished as Exhibit 99.2, which it intends to use in meetings with investors and other stakeholders and make available on its investor relations website. The company notes that the information in these exhibits is being furnished rather than filed under securities laws, which affects how it is treated for legal liability and incorporation into other regulatory documents.
The issuer of GKOS common stock has filed a notice of proposed sale under Rule 144 for 88,055 shares of common stock through Fidelity Brokerage Services LLC. The shares have an stated aggregate market value of 10,126,325.00, based on the information in the filing.
The filing notes that the shares were acquired on 01/08/2026 by exercising a stock option that was originally granted on 03/10/2016, with the purchase price paid in cash. The notice lists 57,434,740 shares of the issuer’s common stock as outstanding and indicates an approximate sale date of 01/08/2026 on the NYSE.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
